P-糖蛋白、多药耐药相关蛋白1、肺耐药相关蛋白和胎盘型谷胱甘肽-S-转移酶在肝母细胞瘤中表达特点及临床意义

The expressions of P-gp,MRP1,LRP,and GST-πin hepatoblastoma

目的探讨4种耐药基因蛋白P-糖蛋白(P-gp)、多药耐药相关蛋白1(MRP1)、肺耐药相关蛋白(LRP)和胎盘型谷胱甘肽-S-转移酶(GST-π)在肝母细胞瘤中的表达特点与肝母细胞瘤病理类型的关系。方法采用免疫组织化学SP法检测20例肝母细胞瘤中P-gp、MRP1、LRP和GST-π的表达强度和分布。结果肝母细胞瘤具有原发耐药性,P-gp和LRP在肝母细胞瘤的多药耐药机制中起主要作用,MRP1起补充作用,GST-π起协同作用;4种耐药基因蛋白在肝母细胞瘤的表达与标本来源无关(P>0.05);P-gp在肝母细胞瘤不同病理类型中呈高强度强阳性表达。结论P-gp、MRP1、LRP和GST-π在肝母细胞瘤中表达的差异性,有助于肝母细胞瘤预后判断以及新辅助化疗中个体化化疗方案的制定。

Objective To explore the relationship between the expressions of P-gp, MRP1, LRP and GST-π with the clinical pathological types of hepatoblastoma, and evaluate their roles in multidrug resistance of hepatoblastoma. Methods Twenty specimens were collected from the hepatoblastoma patients, and the expressions of P-gp, MRP1, LRP and GST- π were detected by streptavidin perosidase（SP）immunohistochemical staining. Results There was primary drug resistance in hepatoblastoma, the P-gp and GST-π played a leading role in the multidrug resistance of hepatoblastoma, and MRP1 and LRP were also involved. There were no relationship among the expressions of P-gp, MRP1, LRP and GST-π in all specimens. All pathological types of hepatoblastoma showed P-gp overexpression. Conclusions The discrepancy expressions of P-gp, MRP1, LRP and GST-π in hepatoblastorna are helpful in the judgment of prognosis and planning of individualized adjuvant chemotherapy.